Thank you for the question, Madam Chair.
On the pathway for use of foreign decisions, a couple of things are important to lay out.
First of all, the companies in the United States would not be required to do any less science. They would still do the same testing. If you started the clock at “I'm going to develop a new product”, they would have to do all the normal tests that they would do here in Canada. All of those would be required in the regulatory text here. Frankly, it's that basis that brings the equity, at least in terms of filing under that pathway, because you'd have to get approved by the EPA and then come to us.
Again, you'd start the clock at the test and you'd still spend the time getting your primary approval, and then you'd come to Canada. The only thing we're not looking at is that primary scientific data to show effectiveness and safety. We trust that, because we work with the EPA and we know their tests are the same tests.
They have to keep the information on hand, so if we need to look at it, we can get it very quickly.